Cell Separation System for Fully Automated Clinical Scale Separation of CD34+ Cells from Leukapheresis Products

Essl, Mike; Stuth, Juliane; Reck, Kristina; Huppert, Volker; Oppen, Nanette von; Balshüsemann, Dirk; Steffens, Gerd; Schmitz, Juergen

doi:10.1016/j.bbmt.2013.12.198

Biology of Blood and Marrow Transplantation

2014

DOI: 10.1016/j.bbmt.2013.12.198

|View full text |Cite

Cell Separation System for Fully Automated Clinical Scale Separation of CD34+ Cells from Leukapheresis Products

Mike Essl

Juliane Stuth

Kristina Reck

et al.

Abstract: This "first-in-man" study demonstrated the safety and feasibility of manufacturing both CD34-TK75+ T cells and [ 18 F]FHBG onsite for administration to patients. A future upfront haploidentical transplant study will employ 100-fold more CD34-TK75 modified T cells.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cell Separation System for Fully Automated Clinical Scale Separation of CD34+ Cells from Leukapheresis Products

Abstract: This "first-in-man" study demonstrated the safety and feasibility of manufacturing both CD34-TK75+ T cells and [ 18 F]FHBG onsite for administration to patients. A future upfront haploidentical transplant study will employ 100-fold more CD34-TK75 modified T cells.

This publication either has no citations yet, or we are still processing them

See others like this or search for similar articles

Contact Info

Product

Resources

About